{"log_id": 6630840038236441311, "direction": 0, "words_result_num": 31, "words_result": [{"probability": {"variance": 0.00119, "average": 0.965504, "min": 0.931008}, "location": {"width": 63, "top": 144, "height": 21, "left": 785}, "words": " HKICN-"}, {"probability": {"variance": 0, "average": 0.997354, "min": 0.997354}, "location": {"width": 16, "top": 138, "height": 18, "left": 1015}, "words": "6"}, {"probability": {"variance": 4e-06, "average": 0.998907, "min": 0.990158}, "location": {"width": 842, "top": 203, "height": 78, "left": 203}, "words": "在高血压伴左心室肥厚患者中进行的一项对照临床试验中,本品通常可很好耐受。最常见"}, {"probability": {"variance": 0.00143, "average": 0.988291, "min": 0.824945}, "location": {"width": 467, "top": 268, "height": 58, "left": 161}, "words": "与药物有关的不良反应是头晕、乏力/疲乏和眩晕"}, {"probability": {"variance": 8.8e-05, "average": 0.995642, "min": 0.957854}, "location": {"width": 844, "top": 330, "height": 76, "left": 207}, "words": "在LIFE研究中,在基线时无糖尿病的病人中,氯沙坦钾组新发生糖尿病的发生率较阿替"}, {"probability": {"variance": 0.000613, "average": 0.990876, "min": 0.85041}, "location": {"width": 887, "top": 375, "height": 75, "left": 165}, "words": "洛尔组低(分别为242位比320位,p<0.001)。因为本研究中无安慰剂组,还不清楚此结果是"}, {"probability": {"variance": 2e-05, "average": 0.997357, "min": 0.982074}, "location": {"width": 455, "top": 437, "height": 55, "left": 168}, "words": "代表了氯沙坦钾的益处,或阿替洛尔的不良反应"}, {"probability": {"variance": 3.2e-05, "average": 0.998421, "min": 0.965244}, "location": {"width": 844, "top": 497, "height": 74, "left": 214}, "words": "在2型糖尿病伴蛋白尿病人中进行的一项对照临床试验中,本品通常可很好耐受。最常见"}, {"probability": {"variance": 4.9e-05, "average": 0.996069, "min": 0.965068}, "location": {"width": 886, "top": 538, "height": 76, "left": 174}, "words": "的与药物有关的不良反应是乏力/疲劳,头晕,低血压和高钾血症(见注意事项,低血压和电解"}, {"probability": {"variance": 0.000235, "average": 0.991905, "min": 0.950811}, "location": {"width": 169, "top": 619, "height": 33, "left": 176}, "words": "质/体液平衡失调)"}, {"probability": {"variance": 0.000786, "average": 0.988865, "min": 0.888227}, "location": {"width": 371, "top": 687, "height": 51, "left": 177}, "words": "本品上市后已报告的其它不良反应包括"}, {"probability": {"variance": 0.000398, "average": 0.992677, "min": 0.882699}, "location": {"width": 889, "top": 704, "height": 74, "left": 179}, "words": "过敏反应:血管性水肿(包括导致气道阻塞的喉及声门肿胀,及/或面、唇、咽和/或舌肿胀)在"}, {"probability": {"variance": 3.1e-05, "average": 0.997836, "min": 0.96493}, "location": {"width": 888, "top": 745, "height": 74, "left": 182}, "words": "极少数服用氯沙坦治疗的病人中有报道。其中部分病人以前曾因服用包括ACE抑制剂在内的其"}, {"probability": {"variance": 0.003509, "average": 0.984775, "min": 0.614161}, "location": {"width": 867, "top": 787, "height": 74, "left": 182}, "words": "他药物而发生过血管性水肿。脉管炎,包括亨诺克-舍恩莱因(亨-舍二氏)紫癜已有极少报道"}, {"probability": {"variance": 0.001496, "average": 0.986948, "min": 0.81497}, "location": {"width": 477, "top": 847, "height": 55, "left": 185}, "words": "胃肠道反应:肝炎(少有报道),肝功能异常,呕吐"}, {"probability": {"variance": 0.000335, "average": 0.993752, "min": 0.919228}, "location": {"width": 384, "top": 894, "height": 48, "left": 186}, "words": "血液系统:贫血,血小板减少(少有报道"}, {"probability": {"variance": 7e-06, "average": 0.998292, "min": 0.99116}, "location": {"width": 287, "top": 941, "height": 43, "left": 188}, "words": "肌肉骨胳系统:肌痛,关节痛"}, {"probability": {"variance": 0.000592, "average": 0.989787, "min": 0.893721}, "location": {"width": 456, "top": 972, "height": 54, "left": 190}, "words": "神经/精神系统:偏头痛,癫痫大发作,味觉障碍"}, {"probability": {"variance": 1.2e-05, "average": 0.997857, "min": 0.98998}, "location": {"width": 154, "top": 1034, "height": 28, "left": 194}, "words": "呼吸系统:咳嗽"}, {"probability": {"variance": 2.4e-05, "average": 0.997914, "min": 0.981346}, "location": {"width": 286, "top": 1064, "height": 44, "left": 195}, "words": "皮肤:荨麻疹,瘙痒,红皮病"}, {"probability": {"variance": 1.6e-05, "average": 0.997164, "min": 0.985329}, "location": {"width": 286, "top": 1105, "height": 43, "left": 196}, "words": "高钾血症和低钠血症已有报道"}, {"probability": {"variance": 2e-06, "average": 0.998886, "min": 0.994812}, "location": {"width": 482, "top": 1135, "height": 54, "left": 197}, "words": "国内有一例与药物有关的不明原因死亡的自发报告"}, {"probability": {"variance": 0, "average": 0.996357, "min": 0.995727}, "location": {"width": 90, "top": 1190, "height": 52, "left": 1013}, "words": "药有"}, {"probability": {"variance": 4e-06, "average": 0.99834, "min": 0.99485}, "location": {"width": 156, "top": 1235, "height": 37, "left": 202}, "words": "实验室检查结果"}, {"probability": {"variance": 0.000441, "average": 0.994524, "min": 0.870144}, "location": {"width": 848, "top": 1239, "height": 74, "left": 241}, "words": "在原发性高血压临床对照试验中,很少有应用本品的病人在实验室参数方面出现临床上有"}, {"probability": {"variance": 0.003648, "average": 0.983696, "min": 0.60063}, "location": {"width": 891, "top": 1283, "height": 73, "left": 204}, "words": "重要意义的变化。1.5%的病人出现高钾血症(血清钾>5.5mEg/L)。在2型糖尿病伴蛋白尿的病"}, {"probability": {"variance": 0.000259, "average": 0.995107, "min": 0.895559}, "location": {"width": 886, "top": 1323, "height": 74, "left": 207}, "words": "人中进行的一项临床研究中,氯沙坦组和安慰剂组分别有9.9%和3.4%的病人出现高钾血症"}, {"probability": {"variance": 1.5e-05, "average": 0.998039, "min": 0.980655}, "location": {"width": 912, "top": 1369, "height": 68, "left": 218}, "words": "(见注意事项,低血压及电解质/体液平衡失调)。ALT的升高较罕见,并在停药后恢复正"}, {"probability": {"variance": 0, "average": 0.999976, "min": 0.999976}, "location": {"width": 26, "top": 1452, "height": 24, "left": 211}, "words": "常"}, {"probability": {"variance": 2e-06, "average": 0.998999, "min": 0.996319}, "location": {"width": 228, "top": 1470, "height": 68, "left": 955}, "words": "杭州默沙东"}, {"probability": {"variance": 0, "average": 0.999769, "min": 0.999433}, "location": {"width": 175, "top": 1513, "height": 49, "left": 1006}, "words": "制药有限公司"}], "language": 3}